Objective: To examine if preoperative microalbuminuria is associated with an increased risk of long-term adverse outcomes following elective cardiac surgery and if it provides additional prognostic information beyond the European System for Cardiac Operative Risk Evaluation (EuroSCORE). Methods: In a prospective follow-up study, we included 1049 patients undergoing elective cardiac surgery from 1 April 2005 to 30 September 2007. Microalbuminuria (urine albumin/creatinine ratio between 2.5 and 25 mg mmol À1 ) was assessed preoperatively in a morning spot-urine sample. We used population-based medical registries for follow-up from day 31 until day 365 postoperatively, and compared all-cause death, myocardial infarction, cerebral stroke and a composite outcome of severe infections including septicaemia, deep or superficial sternal wound infection, or leg wound infection among patients with or without microalbuminuria using Cox proportional hazard and competing risk regressions. Results: Microalbuminuria was found in 175 (18.5%) out of 947 patients available for follow-up. The adjusted risks of all-cause death (adjusted hazard ratio 2.3 (95% confidence interval 1.1-4.9)), stroke (adjusted hazard ratio 2.9 (95% confidence interval 1.1-7.8)) and severe infection composite outcome (adjusted hazard ratio 2.4 (95% confidence interval 1.2-4.9)) were doubled to tripled in patients with preoperative microalbuminuria. The risk of myocardial infarction was not increased. Adding information on microalbuminuria improved the predictive accuracy of the EuroSCORE regarding mortality (areas under receiver operating characteristic curves were: for the EuroSCORE 0.73 (95% confidence interval 0.65-0.81) and for EuroSCORE + microalbuminuria 0.76 (95% confidence interval 0.68-0.83). Conclusions: Preoperative microalbuminuria is associated with an increased risk of long-term adverse outcomes in patients undergoing elective cardiac surgery, and it appears to provide prognostic information on mortality. #
Introduction
Microalbuminuria (MA) reflects the glomerular component of a systemic capillary dysfunction and is a sensitive marker of cardiovascular risk and mortality in both diabetic and nondiabetic patients [1] [2] [3] . Increased urinary albumin excretion is often present in patients with established atherosclerotic disease, as also in patients with early asymptomatic vascular disease as well as in patients with hypertension or heart failure [4] [5] [6] [7] . Information on MA was found to improve existing risk prediction in patients with acute myocardial infarction [4] , and it is also closely related to metabolic syndrome, a clustering of several cardiovascular risk factors, found to be a powerful risk factor for adverse outcomes in patients undergoing coronary bypass surgery [5, 6] .
In cardiac surgery, we face a need to revise existing risk prediction models and address a wider spectrum of adverse outcomes in longer postoperative time-spans [7] . In this context, preoperative MA has attracted only very modest attention. However, in a recently published article, we assessed the prevalence of MA and its association with shortterm adverse outcomes after elective cardiac surgery [8] . We found no significant association between MA and early allcause death, but a significantly increased risk of septicaemia and a longer intensive care unit and total hospital stay in patients with MA [8] . When considering the long-term adverse outcomes following cardiac surgery, it still remains unknown whether patients with preoperative MA independently fare a worse prognosis than patients without MA.
Accordingly, the aims of the present study were to evaluate whether preoperative MA was associated with adverse postoperative outcomes beyond the early postoperative period in patients undergoing elective cardiac surgery and, if so, whether assessment of MA upholds predictive information alone and in a combined model beyond currently acknowledged risk assessments.
Materials and methods

Design and setting
We conducted a prospective follow-up study in the Central Denmark Region, which has a mixed rural- 
Study population
Inclusion criteria were (1) age greater than 18 years and (2) elective cardiac surgery (surgery performed more than 2 days after planning of the procedure) -including on-and offpump coronary artery bypass grafting, valve surgery, thoracic aortic surgery, pulmonary thromboendarterectomy, adult congenital heart disease procedures or combined procedures. Exclusion criteria were (1) severe renal disease defined as a serum creatinine value above 200 mmol l À1 or (2) macroalbuminuria defined as a urine albumin/creatinine excretion ratio (UACR) above 25 mg mmol À1 and (3) previous heart or renal transplant surgery.
During the study period, a total of 2216 patients underwent cardiac surgery at the department. Patient screening and recruitment were done by a project nurse working half-time. Approximately 50% (n = 1193) of the potential candidates for the study were, therefore, screened consecutively. Seventy-eight were excluded because of acute surgery, and 54 had known renal disease with serum creatinine above 200 mmol l À1 . The remaining 1061 patients were invited to participate. Only 12 patients did not accept participation and 1049 patients were included.
Laboratory analyses
A preoperative fasting blood sample and a morning spoturine sample were collected and analysed at the Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark.
MA was defined as an UACR between 2.5 and 25 mg mmol À1 . Using a preoperative urine sample, urinary albumin (mg l À1 ) was assessed quantitatively by immunoturbidimetry and urinary creatinine (mmol l À1 ) was estimated by an enzymatic colorimetric test. The sensitivity level for urinary albumin was 7 mg l À1 . Because UACR was constructed by dividing urinary albumin with urinary creatinine, albumin values below 7 mg l À1 could not contribute to an exact UACR (mg mmol À1 ). We defined UACR to be 0.1 mg mmol À1 in these patients.
Study outcomes
The association between MA and all-cause death, myocardial infarction or percutaneous coronary intervention (PCI), and stroke was examined, respectively, and as a composite outcome. We also compared three composite outcomes regarding severe infections consisting of (1) deep sternal wound infection and septicaemia (defined as a positive bacteriaemic blood sample and/or clinical sepsis), (2) deep sternal or superficial sternal wound infection and septicaemia and (3) deep sternal or superficial sternal wound infection, septicaemia or leg wound infection (at the site of extracted bypass graft).
Since 1968, all Danish residents have been assigned a unique civil registration number that allows unambiguous record linkage between the Danish health databases. We used the Danish Registry of Patients, the Western Denmark Heart Registry and the National Register of Causes of Death for assessing outcomes.
The Danish National Registry of Patients was established in 1977, and holds data on all hospitalisations from somatic Danish hospitals, including dates of admission and discharge, procedures performed and up to 20 discharge diagnoses coded by physicians according to the International Classification of Diseases (8th revision (ICD-8) until the end of 1993, end 10th revision (ICD-10) thereafter). Since 1995, discharges from emergency rooms and outpatient clinics have also been included in this registry. The Western Denmark Heart Registry, established in 1999, is a regional clinical register including detailed patient baseline characteristics, data for all cardiac procedures performed and per-and postoperative outcomes. The National Register of Causes of Death is a complete registry of dates and all causes of death in Denmark since 1973.
Covariates
Baseline characteristics and in-hospital peroperative data were collected from a preoperative interview, patient medical records, the Western Denmark Heart Registry, the Prescription Database and the Danish National Registry of Patients. For each patient, a case-report-form was used.
Baseline data included age, gender, smoking habits, body mass index, blood pressure, prior ischaemic peripheral-, cerebral-or cardiovascular disease, history of arrhythmias, diabetes and dyslipidaemia, cardiac ejection fraction, European System for Cardiac Operative Risk Evaluation (EuroSCORE), Charlson Comorbidity Index, glomerular filtration rate as estimated by the Cockcroft-Gault formula, serum levels of creatinine, electrolytes, albumin, glucose, white and red blood cell counts, platelets and the UACR. The EuroSCORE was obtained by linkage to the Western Denmark Heart Registry.
The Charlson Comorbidity Index classifies co-morbidity and, in longitudinal studies, it predicts both short-and longterm mortality [9] . The index was constructed by combining data from the case-report form with data from the National Registry of Patients, and for analyses, we categorised the index score into three levels of co-morbidity: 0 ('low'), 1-2 ('medium') and >2 ('high').
Data from the Western Denmark Heart Registry on the peroperative covariates included type of operation, cardiopulmonary bypass time, aortic cross-clamp time and number and type of grafts.
From a regional prescription database, we obtained data on the use of medication up to 180 days preoperatively and 365 days postoperatively. The database contains data on all redeemed prescriptions at all pharmacies in the region since 1998. The main variables are the unique civil registration number, name and drug code, package identifier (enabling identification of brand, quantity and formulation of the drug) and dates of refill.
Statistical analyses
Baseline characteristics and per-and postoperative variables were compared between groups with and without MA using Fisher's exact test, independent t-tests and the Mann-Whitney test. Continuous variables are presented as medians with interquartile range (IQR) and categorical data as counts and frequencies. Cumulative risk curves of all-cause death and the combined outcomes were constructed. The associations between MA and the outcomes (individual and composite) were examined using multivariate competing risk regressions or Cox regression analyses (for all-cause death and the composite of all-cause death, stroke and myocardial infarction/PCI) with adjustment for possible baseline confounding factors and postoperative use of prescribed cardiovascular drugs. The latter were included as timedependent covariates.
In the competing risk regression models, all-cause death was considered as the potential competing failure event impeding the non-fatal outcomes of interest. All multivariate models were also analysed using logistic regression, which did not substantially change the risk estimates, but allowed for discrimination analyses of the multivariate models and construction of receiver operating characteristic curves. Calibration analyses were performed using the HosmerLemeshow tests. Furthermore, the association between the continuous level of UACR and risk of various outcomes was also estimated using spline regression to identify any nonlinear patterns. Finally, analyses were done in separate subgroups of patients undergoing only coronary bypass surgery, cardiac valve surgery alone or a combination of bypass-and valve surgery.
A two-tailed p-value less than 0.05 was considered statistically significant. Analyses were performed using the Stata W 11.0 package (Stata Corp LP, TX, USA).
Results
Study cohort and surgical characteristics
Baseline and peroperative patient characteristics according to presence of MA are displayed in Tables 1 and 2 , respectively. A preoperative in-hospital baseline serum creatinine analysis revealed 11 patients with levels above our exclusion criteria. The UACR assessment resulted in the exclusion of 22 patients with macroalbuminuria, and another 54 patients were excluded due to failure of the UACR analyses. Fourteen patients died within 30 days of surgery, and during follow-up one patient emigrated, leaving 947 patients available for complete long-term follow-up (Fig. 1) . The overall prevalence of MA in the cohort was 18.5% (n = 175). The logistic EuroSCORE was available for all included patients and the median logistic EuroSCORE of the study cohort was 4 (IQR 2-8).
Patients with MA had a slightly higher level of co-morbidity at baseline. They had a higher median EuroSCORE, and the median age was 3 years greater than the normoalbuminuric patients. Likewise, there were minor differences in smoking habits, diabetes, previous stroke, atrial fibrillation, cardiac ejection fraction, serum creatinine and the glomerular filtration rate. Use of angiotensin-converting enzyme inhibitors and calcium-channel blockers tended to be more frequent in microalbuminuric patients, whereas the use of beta blockers, angiotensin-II receptor blockers or lipidlowering agents was similar between groups.
Patients with MA had less solitary bypass procedures and more combined procedures performed, but there were no differences between groups with regard to use of extracorporeal circulation and aortic cross-clamp time. The number of grafted coronary vessels in patients undergoing on-or off-pump coronary artery bypass surgery was slightly lower in the MA group.
Associations between MA and postoperative adverse outcomes
The crude and adjusted associations between MA and study outcomes are displayed in Table 3 . The cumulative incidence of all-cause mortality and the composite infection outcome during the follow-up period are shown in Figs. 2 and 3, respectively.
MA was strongly associated with all-cause death (adjusted hazard ratio (HR) 2.3 (95% confidence interval (CI) 1.1-4.9)), when adjusted for the logistic EuroSCORE and the modified Charlson Comorbidity Index.
MA did not appear to be associated with myocardial infarction/PCI; however, it was associated with a higher risk of cerebral stroke (adjusted HR 2.9 (95% CI 1.1-7.8). Moreover, MA was independently associated with the composite adverse outcome consisting of all-cause death, myocardial infarction/PCI and stroke (adjusted HR 1.7 (95% CI 1.0-3.0)), which occurred in 60 (6%) patients.
The first combined outcome regarding severe infection consisted of deep sternal wound infection or septicaemia, and occurred in only 14 (1.5%) patients. MA appeared to be associated with an increased risk of this infection outcome (adjusted HR 2.0 (95% CI 0.6-6.8)). Although this association was not statistically significant, the estimate remained robust, even when events of superficial sternal wound infection requiring surgical intervention alone (adjusted HR 2.3 (95% CI 1.0-5.5)) or in combination with leg wound infection requiring surgical intervention (adjusted HR 2.4 (95% CI 1.2-4.9)) were added to the combined infection outcome.
Any further adjustment for other patient characteristics or postoperative medication use did not change the risk estimates substantially.
The adjusted relationship between continuous UACR and the risk of all-cause death was significant. Each 1 mg mmol À1 increment in UACR was associated with and increased odds ratio of 1.12 (95% CI 1.03-1.18). In a continuous spline function, we found no specific UACR cutoff level associated with an increased risk of postoperative all-cause death.
Subgroups
Considering all-cause death, the descriptive analyses were then restricted to the subgroups of patients undergoing (1) bypass surgery alone (n = 403) where none out of nine dead patients had MA, (2) valve surgery alone (n = 272) where 8 out of 10 dead patients had MA and (3) combined bypass and valve procedures (n = 153) where 2 out of 5 dead patients had MA. Table 4 shows the area under the receiver operating characteristic curves (AUCs) for MA, EuroSCORE, Charlson Comorbidity Index alone and for the multivariate logistic models regarding all-cause death. The logistic EuroSCORE predicted all-cause death (AUC 0.73 (95% CI 0.65-0.81)) more accurately than did MA (AUC 0.64 (95% CI 0.55-0.73)) and Charlson Comorbidity Index (AUC 0.70 (95% CI 0.63-0.78)). In a model including both EuroSCORE and MA, AUC reached 0.76 (95% CI 0.68-0.83), and, thereafter, adding information on Charlson Comorbidity Index again slightly increased AUC up to 0.78 (95% CI 0.71-0.85).
Risk prediction
Considering other study outcomes, the AUCs for MA alone was 0.52 (95% CI 0.45-0.60) for myocardial infarction/PCI, 0.61 (95% CI 0.48-0.74) for stroke and 0.63 (95% CI 0.55-0.71) for the third composite severe infection outcome.
Hosmer-Lemeshow tests for calibration showed good agreement for both the multivariate logistic regression models including (1) EuroSCORE + MA ( p-value = 0.19, chi 2 = 4.7) and (2) EuroSCORE + MA + Charlson Comorbidity Index ( p-value = 0.47, chi 2 = 2.6).
Causes of death
Sixteen patients had cardiovascular deaths, five had infections-related deaths and the remaining 10 had other causes (including five patients with 'Unknown cause of [ ( ) T D $ F I G ] [ ( ) T D $ F I G ] mortality' (ICD-10: R99.9)). A Fisher's exact test showed equal distribution of MA across the three categories of causes of death.
Discussion
In the present study, the presence of MA was found to be independently associated with increased all-cause mortality, stroke and a composite outcome consisting of all-cause death, myocardial infarction/PCI and stroke in a prospective cohort of patients undergoing elective cardiac surgery. Furthermore, we found a significant association between MA and severe postoperative infections. Preoperative assessment of MA predicted all-cause death, and appears to provide only modest, however potentially important, additional prognostic information compared with Euro-SCORE alone.
The prevalence of MA (18.5%) in our study was lower than reported in a population of 257 diabetic patients undergoing coronary artery bypass grafting [10] . At a mean follow-up of 31 (AE16) months, Yorgancioglu and colleagues observed only 12 deaths and found no significant difference between diabetics with and without MA regarding fatal events [10] .
MA was not associated with an increased risk of postoperative myocardial infarction/PCI in our study. On the contrary, the adjusted estimate (HR 0.5) even suggested a negative association, but CI was very wide, and based on existing knowledge and the relative few events reported in this study, we believe the estimate is more likely to be a chance finding rather than reflecting a biological protective mechanism of MA.
When analyses were restricted to subgroups, the patients undergoing bypass surgery alone had very low mortality, whereas the descriptive statistics showed higher mortality among patients with MA undergoing valve surgery alone. This indicates that especially patients with MA undergoing valve procedure may be at higher risk. The subgroups were small and regression analyses were impossible.
The EuroSCORE is regarded as the most accurate predictor of postoperative mortality, but was constructed to predict 30-day mortality only and, furthermore, it overestimates risk in low-risk patients and underestimates mortality in high-risk patients [7] . Evidence is sparse and conflicting as to how accurately the EuroSCORE predicts longer time-span mortality in patients undergoing cardiac surgery [7, 11, 12] . Models designed to predict long-term adverse outcomes after cardiac surgery are not available, but seem desirable [7] . In this study, MA was strongly associated with adverse outcomes, but MA alone did not distinguish survivors from non-survivors accurately (see Table 4 ). The present results do not indicate that routine assessment of preoperative MA should be recommended in elective cardiac surgery. However, we cannot rule out that information on MA may provide new knowledge that can lead to the identification of a subgroup of patients that may benefit from for example, changes in postoperative medical treatment. Although the predictive accuracy of MA was limited in the present study, we still suggest, owing to our results, that MA should be considered as a potential risk marker in a larger study addressing a revision of multivariate risk prediction models in patients undergoing cardiac surgery.
Our study has both strengths and limitations: we studied a well-defined cohort that was representative of the patient population undergoing cardiac surgery at our department. We had a practically complete follow-up on all included patients, as our design relied on national health registries with complete coverage. Recruitment of participants was prospective and independent of the presence of MA. We found no indication supporting a skewed distribution of the 54 patients who were excluded due to failure of UACR analysis or among the patients who died within day 30, postoperatively. In addition, UACR was not known by the physicians treating the patients and the risk of information bias was therefore minimal. Through the case-report form and the national health registries, we were able to compute the Charlson Comorbidity Index and, thereby, effectively adjust for the influence of baseline co-morbidity on the association between MA and the postoperative outcomes. When considering registry data validity, the predictive values have previously been reported to be high (approximately 80-99%) for several of the outcomes in our study, including myocardial infarction and stroke [13] [14] [15] . Any misclassification would, in any case, most likely be independent of the presence of MA and would bias the findings toward the null hypothesis. The one-time measurement of UACR may introduce a limitation into the study because of intra-individual variation in urinary albumin excretion with time. Three consecutive samples over 3 days are considered more optimal, but the use of one morning spot-urine sample for UACR assessment is, however, considered a well-validated, inexpensive and feasible approach [16, 17] .
In conclusion, the preoperative presence of MA was associated with an increased risk of long-term adverse outcomes in patients undergoing elective cardiac surgery. Preoperative screening for MA, however, provided only modest prognostic information, and future studies are warranted to further clarify the role of MA in long-term risk assessment in cardiac surgery. 
